Arlene Siefker-Radtke

Arlene Siefker-Radtke is an expert in rare bladder cancer variants and has been a key investigator in FGFR-targeted therapy and ADC trials. Her work on small cell and variant histology bladder cancers has defined treatment approaches for these challenging subtypes. She contributes to enfortumab vedotin combination studies in both common and rare urothelial cancer populations.